摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-(trityloxy)heptanoic acid | 173152-99-3

中文名称
——
中文别名
——
英文名称
7-(trityloxy)heptanoic acid
英文别名
7-trityloxyheptanoic acid;7-trityloxy-heptanoic acid
7-(trityloxy)heptanoic acid化学式
CAS
173152-99-3
化学式
C26H28O3
mdl
——
分子量
388.507
InChiKey
NUORLXYNQUZBNG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.9
  • 重原子数:
    29
  • 可旋转键数:
    11
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    醇和醚在室温下直接酰胺化成酰胺:合成的“酰胺策略”
    摘要:
    最后一分钟的交易:据报道,醚和醇在酰胺的直接内酯化反应在室温下,在温和条件下进行(见方案)。这允许在合成序列中有效节省多达两个非生产性的顺序脱保护操作。描述了机理研究,并概述了利用该官能团的双重鲁棒性/后期选择性激活特性的新“酰胺策略”。
    DOI:
    10.1002/chem.201203906
  • 作为产物:
    描述:
    1,7-庚二醇吡啶 、 2,2,6,6-tetramethyl-piperidine-N-oxyl 、 sodium hypochloritesodium chlorite 作用下, 以 aq. phosphate buffer 、 二氯甲烷乙腈 为溶剂, 生成 7-(trityloxy)heptanoic acid
    参考文献:
    名称:
    醇和醚在室温下直接酰胺化成酰胺:合成的“酰胺策略”
    摘要:
    最后一分钟的交易:据报道,醚和醇在酰胺的直接内酯化反应在室温下,在温和条件下进行(见方案)。这允许在合成序列中有效节省多达两个非生产性的顺序脱保护操作。描述了机理研究,并概述了利用该官能团的双重鲁棒性/后期选择性激活特性的新“酰胺策略”。
    DOI:
    10.1002/chem.201203906
点击查看最新优质反应信息

文献信息

  • Mono or bicyclic DNA gyrase inhibitors
    申请人:F. HOFFMANN-LA ROCHE AG
    公开号:EP0675122A2
    公开(公告)日:1995-10-04
    The present invention relates to mono- or bicyclic compounds of the general formula wherein X1is -S- or -SO-; R1is hydrogen, halogen or lower alkyl, optionally substituted by halogen ; R2is hydrogen, hydroxy, amino, lower alkylamino, di-lower alkylamino, optionally substituted lower alkoxy or a group -OP; OPis an easily hydrolyzable group; R3is hydrogen, hydroxy, lower alkyl, halogen or a group -OP; R4is halogen, hydroxy or a group -OP; R5is hydrogen, cyano, optionally substituted esterified carboxy or optionally substituted amidated (thio)carboxy, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted heterocyclyl; R6is -NR7-A, -N=B or optionally substituted heterocyclyl, in which R7 is hydrogen or lower alkyl, A is optionally substituted iminoyl, optionally substituted (thio)acyl, optionally substituted esterified carboxy, optionally substituted amidated (thio)carboxy or optionally substituted heterocyclyl and B is optionally substituted alkylidene; R0is cyano, optionally substituted esterified carboxy or optionally substituted heterocyclyl, or wherein R0 and R6taken together represent a group         -CO-O-Q-X2-N(R7)-, wherein R7is as above, and X2is (thio)carbonyl or heterocyclyl; Qis -CH(R8)- or -CH(R8)-W-; R8is hydrogen or optionally substituted lower alkyl, and Wis optionally substituted mono-, di-, tri-, tetra- or pentamethylene, provided that when W is monomethylene X2 is other than (thio)carbonyl, and pharmaceutically acceptable salts of the mono- or bicyclic compounds of formula I carrying an acidic and/or basic substituent. These compounds of formula I as well as their pharmaceutically acceptable salts inhibit DNA gyrase activity in bacteria and possess antibiotic, especially antibacterial activity against microorganisms and can be used in the control or prevention of infectious diseases.
    本发明涉及通式如下的单环或双环化合物 其中 X1是-S-或-SO-; R1是氢、卤素或低级烷基,任选被卤素取代; R2 是氢、羟基、氨基、低级烷基氨基、二低级烷基氨基、任选被取代的低级烷氧基或基团 -OP; OP 是易水解基团; R3 是氢、羟基、低级烷基、卤素或基团 -OP R4 是卤素、羟基或基团 -OP R5是氢、氰基、任选取代的酯化羧基或任选取代的酰胺化(硫代)羧基、任选取代的烷基、任选取代的烯基或任选取代的杂环基; R6是-NR7-A、-N=B或任选取代的杂环基,其中R7是氢或低级烷基,A是任选取代的亚氨基酰基、任选取代的(硫代)酰基、任选取代的酯化羧基、任选取代的酰胺化(硫代)羧基或任选取代的杂环基,B是任选取代的亚烷基; R0 是氰基、任选取代的酯化羧基或任选取代的杂环基,或其中 R0 和 R6 合在一起代表一个基团 -CO-O-Q-X2-N(R7)-、 其中 R7 如上,以及 X2 是(硫代)羰基或杂环基; Q是-CH(R8)-或-CH(R8)-W-; R8 是氢或任选取代的低级烷基,以及 Wis 任选取代的一亚甲基、二亚甲基、三亚甲基、四亚甲基或五亚甲基,但当 W 为一亚甲基时,X2 不是(硫代)羰基、 和 带有酸性和/或碱性取代基的式 I 单环或双环化合物的药学上可接受的盐。 这些式 I 化合物及其药学上可接受的盐类可抑制细菌中 DNA 回旋酶的活性,并具有抗生素活性,特别是对微生物的抗菌活性,可用于控制或预防传染性疾病。
  • New Antibacterial Agents Derived from the DNA Gyrase Inhibitor Cyclothialidine
    作者:Peter Angehrn、Stefan Buchmann、Christoph Funk、Erwin Goetschi、Hans Gmuender、Paul Hebeisen、Dirk Kostrewa、Helmut Link、Thomas Luebbers、Raffaello Masciadri、Joergen Nielsen、Peter Reindl、Fabienne Ricklin、Anne Schmitt-Hoffmann、Frank-Peter Theil
    DOI:10.1021/jm0310232
    日期:2004.3.1
    Cyclothialidine (1, Ro 09-1437) is a potent DNA gyrase inhibitor that was isolated from Streptomyces filipinensis NR0484 and is a member of a new family of natural products. It acts by competitively inhibiting the ATPase activity exerted by the B subunit of DNA gyrase but barely exhibits any growth inhibitory activity against intact bacterial cells, presumably due to insufficient permeation of the cytoplasmic membrane. To explore the antibacterial potential of 1, we developed a flexible synthetic route allowing for the systematic modification of its structure. From a first set of analogues, structure-activity relationships (SAR) were established for different substitution patterns, and the 14-hydroxylated, bicyclic core (X) of 1 seemed to be the structural prerequisite for DNA gyrase inhibitory activity. The variation of the lactone ring size, however, revealed that activity can be found among 11- to 16-membered lactones, and even seco-analogues were shown to maintain some enzyme inhibitory properties, thereby reducing the minimal structural requirements to a rather simple, hydroxylated benzyl sulfide (XI). On the basis of these "minimal structures" a modification program afforded a number of inhibitors that showed in vitro activity against Gram-positive bacteria. The best activities were displayed by 14-membered lactones, and representatives of this subclass exhibit excellent and broad in vitro antibacterial activity against Gram-positive pathogens, including Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis, and overcome resistance against clinically used drugs. By improving the pharmacokinetic properties of the most active compounds (94, 97), in particular by lowering their lipophilic properties, we were able to identify congeners of cyclothialidine (1) that showed efficacy in vivo.
  • US5589473A
    申请人:——
    公开号:US5589473A
    公开(公告)日:1996-12-31
  • US5594135A
    申请人:——
    公开号:US5594135A
    公开(公告)日:1997-01-14
  • US5665746A
    申请人:——
    公开号:US5665746A
    公开(公告)日:1997-09-09
查看更多

同类化合物

(3-三苯基甲氨基甲基)吡啶 非马沙坦杂质1 隐色甲紫-d6 隐色孔雀绿-d6 隐色孔雀绿 隐色乙基结晶紫 降钙素杂质10 酸性黄117 酸性蓝119 酚酞啉 酚酞二硫酸钾水合物 萘,1-甲氧基-3-甲基 苯酚,4-(1,1-二苯基丙基)- 苯甲醇,4-溴-a-(4-溴苯基)-a-苯基- 苯甲酸,4-(羟基二苯甲基)-,甲基酯 苯甲基N-[(2(三苯代甲基四唑-5-基-1,1联苯基-4-基]-甲基-2-氨基-3-甲基丁酸酯 苯基双-(对二乙氨基苯)甲烷 苯基二甲苯基甲烷 苯基二[2-甲基-4-(二乙基氨基)苯基]甲烷 苯基{二[4-(三氟甲基)苯基]}甲醇 苯基-二(2-羟基-5-氯苯基)甲烷 苄基2,3,4-三-O-苄基-6-O-三苯甲基-BETA-D-吡喃葡萄糖苷 苄基 5-氨基-5-脱氧-2,3-O-异亚丙基-6-O-三苯甲基呋喃己糖苷 苄基 2-乙酰氨基-2-脱氧-6-O-三苯基-甲基-alpha-D-吡喃葡萄糖苷 苄基 2,3-O-异亚丙基-6-三苯甲基-alpha-D-甘露呋喃糖 膦酸,1,2-乙二基二(磷羧基甲基)亚氨基-3,1-丙二基次氮基<三价氮基>二(亚甲基)四-,盐钠 脱氢奥美沙坦-2三苯甲基奥美沙坦脂 美托咪定杂质28 绿茶提取物茶多酚陕西龙孚 结晶紫 磷,三(4-甲氧苯基)甲基-,碘化 碱性蓝 硫代硫酸氢 S-[2-[(3,3,3-三苯基丙基)氨基]乙基]酯 盐酸三苯甲基肼 白孔雀石绿-d5 甲酮,(反-4-氨基-4-甲基环己基)-4-吗啉基- 甲基三苯基甲基醚 甲基6-O-(三苯基甲基)-ALPHA-D-吡喃甘露糖苷三苯甲酸酯 甲基3,4-O-异亚丙基-2-O-甲基-6-O-三苯甲基吡喃己糖苷 甲基2-甲基-N-{[4-(三氟甲基)苯基]氨基甲酰}丙氨酸酸酯 甲基2,3,4-三-O-苯甲酰基-6-O-三苯甲基-ALPHA-D-吡喃葡萄糖苷 甲基2,3,4-三-O-苄基-6-O-三苯甲基-ALPHA-D-吡喃葡萄糖苷 甲基2,3,4-三-O-(苯基甲基)-6-O-(三苯基甲基)-ALPHA-D-吡喃半乳糖苷 甲基-6-O-三苯基甲基-alpha-D-吡喃葡萄糖苷 甲基(1-trityl-1H-imidazol-4-yl)乙酸酯 甲基 2,3,4-三-O-苄基-6-O-三苯基甲基-ALPHA-D-吡喃甘露糖苷 环丙胺,1-(1-甲基-1-丙烯-1-基)- 溶剂紫9 溴化N,N,N-三乙基-2-(三苯代甲基氧代)乙铵 海涛林